Drug Trial Radar · NCT02760797
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
May 9, 2016
Primary completion
Apr 6, 2018
Study completion Apr 6, 2018
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced or metastatic solid tumors that are not amenable to standard treatment. This study will be conducted in two parts: a dose-finding stage (Part I) and an expansion stage (Part II).
Conditions
- Neoplasms
Interventions
EmactuzumabDrug
Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
RO7009789Drug
RO7009789 will be administered IV every 3 weeks (every cycle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to 6 weeks from Day (D) 1 of Cycle (C) 1 (cycle = 3 weeks)
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Memorial Sloan-Kettering Cancer Center
New York, New York
University Pennsylvania Hospital
Philadelphia, Pennsylvania
Cliniques Universitaires St-Luc
Brussels, Belgium
Centre Leon Berard; Departement Oncologie Medicale
Lyon, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Institut Gustave Roussy; Sitep
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.